Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
Annexin-A1
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "Annexin-A1" in MCE Product Catalog:
2
2 Cited Publications
Target:
PF-04217903 is an orally active, highly selective ATP-competitive c-Met kinase inhibitor with a Ki value of 4.8 nM and a Kd value of 4.5 nM. PF-04217903 blocks c-Met and HGF signaling pathways, inhibits MET phosphorylation, and blocks downstream MAPK, PI3K/AKT and PLCγ1 pathways. PF-04217903 suppresses tumor proliferation, survival, migration, invasion, angiogenesis and metastasis, induces apoptosis, and enhances efferocytosis, Annexin A1 expression and resolution of inflammation. PF-04217903 retains activity against several c-Met mutants (M1131T, V1220I, H1094R). PF-04217903 increases the incidence of subarachnoid hemorrhage and reduces survival rate without altering aneurysm formation, and also prevents lymph node metastasis induced by VEGF inhibition. PF-04217903 is applicable to research related to tumors (pancreas, stomach, lung, brain, colon, breast, kidney, melanoma, etc.), intracranial aneurysms and inflammatory diseases (gouty arthritis, neutrophilic pleuritis) [1] .
2
2 Cited Publications
Target:
PF-04217903 mesylate is an orally active, highly selective ATP-competitive c-Met kinase inhibitor with a Ki value of 4.8 nM and a Kd value of 4.5 nM. PF-04217903 mesylate blocks c-Met and HGF signaling pathways, inhibits MET phosphorylation, and blocks downstream MAPK, PI3K/AKT and PLCγ1 pathways. PF-04217903 mesylate suppresses tumor proliferation, survival, migration, invasion, angiogenesis and metastasis, induces apoptosis, and enhances efferocytosis, Annexin A1 expression and resolution of inflammation. PF-04217903 mesylate retains activity against several c-Met mutants (M1131T, V1220I, H1094R). PF-04217903 mesylate increases the incidence of subarachnoid hemorrhage and reduces survival rate without altering aneurysm formation, and also prevents lymph node metastasis induced by VEGF inhibition. PF-04217903 mesylate is applicable to research related to tumors (pancreas, stomach, lung, brain, colon, breast, kidney, melanoma, etc.), intracranial aneurysms and inflammatory diseases (gouty arthritis, neutrophilic pleuritis) [1] .
2
2 Cited Publications
Cat. No.: HY-P7512
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: ANXA1; Annexin-1; Prev. ANX1; Annexin I (Lipocortin I); Prev. LPC1; ANXA1 Protein; Phospholipase A2 Inhibitory Protein; Lipocortin I; Chromobindin-9; Annexin I; Calpactin II; Annexin; Calpactin-2; P35; Annexin A1; Epididymis Secretory Sperm Binding Protein
Species:
Human
Source:
E. coli
2
2 Cited Publications
Cat. No.: HY-P72078
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ANXA1; Annexin-1; Prev. ANX1; Annexin I (Lipocortin I); Prev. LPC1; ANXA1 Protein; Phospholipase A2 Inhibitory Protein; Lipocortin I; Chromobindin-9; Annexin I; Calpactin II; Annexin; Calpactin-2; P35; Annexin A1; Epididymis Secretory Sperm Binding Protei
Species:
Mouse
Source:
E. coli
1
1 Cited Publications
Cat. No.: HY-P1099
CAS No.: 256447-08-2
Target:
Research Areas:
Cat. No.: HY-P11491
CAS No.: 164466-66-4
Research Areas:
Ac2-26 (mouse) is the N-terminal active peptide of Annexin A1 (AnxA1; AxA1). Ac2-26 (mouse) regulates the inflammatory response by modulating the formyl peptide receptor (FPR) signaling pathway. Ac2-26 (mouse) can promote the release of chemokines and inhibit the production of ROS. Ac2-26 (mouse) can be used for the research of inflammation, such as rheumatoid arthritis [1].
Cat. No.: HY-P1099A
Target:
Research Areas:
Cat. No.: HY-12017B
CAS No.: 1159490-85-3
Target:
PF-04217903 phenolsulfonate is an orally active, highly selective ATP-competitive c-Met kinase inhibitor with a Ki value of 4.8 nM and a Kd value of 4.5 nM. PF-04217903 phenolsulfonate blocks c-Met and HGF signaling pathways, inhibits MET phosphorylation, and blocks downstream MAPK, PI3K/AKT and PLCγ1 pathways. PF-04217903 phenolsulfonate suppresses tumor proliferation, survival, migration, invasion, angiogenesis and metastasis, induces apoptosis, and enhances efferocytosis, Annexin A1 expression and resolution of inflammation. PF-04217903 phenolsulfonate retains activity against several c-Met mutants (M1131T, V1220I, H1094R). PF-04217903 phenolsulfonate increases the incidence of subarachnoid hemorrhage and reduces survival rate without altering aneurysm formation, and also prevents lymph node metastasis induced by VEGF inhibition. PF-04217903 phenolsulfonate is applicable to research related to tumors (pancreas, stomach, lung, brain, colon, breast, kidney, melanoma, etc.), intracranial aneurysms and inflammatory diseases (gouty arthritis, neutrophilic pleuritis) [1] .
Cat. No.: HY-P700657
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: ANXA1; Annexin-1; Prev. ANX1; Annexin I (Lipocortin I); Prev. LPC1; ANXA1 Protein; Phospholipase A2 Inhibitory Protein; Lipocortin I; Chromobindin-9; Annexin I; Calpactin II; Annexin; Calpactin-2; P35; Annexin A1; Epididymis Secretory Sperm Binding Protei
Species:
Cynomolgus
Source:
E. coli
Cat. No.: HY-P71713
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ANXA1; Annexin-1; Prev. ANX1; Annexin I (Lipocortin I); Prev. LPC1; ANXA1 Protein; Phospholipase A2 Inhibitory Protein; Lipocortin I; Chromobindin-9; Annexin I; Calpactin II; Annexin; Calpactin-2; P35; Annexin A1; Epididymis Secretory Sperm Binding Protei
Species:
Mouse
Source:
P. pastoris
Cat. No.: HY-P991864
Synonyms: MDX-124
Target:
Research Areas:
Annexuzlimab is a humanised IgG1 monoclonal antibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma [1] .
Cat. No.: HY-12017C
CAS No.: 1159490-83-1
Target:
PF-04217903 phosphate is an orally active, highly selective ATP-competitive c-Met kinase inhibitor with a Ki value of 4.8 nM and a Kd value of 4.5 nM. PF-04217903 phosphate blocks c-Met and HGF signaling pathways, inhibits MET phosphorylation, and blocks downstream MAPK, PI3K/AKT and PLCγ1 pathways. PF-04217903 phosphate suppresses tumor proliferation, survival, migration, invasion, angiogenesis and metastasis, induces apoptosis, and enhances efferocytosis, Annexin A1 expression and resolution of inflammation. PF-04217903 phosphate retains activity against several c-Met mutants (M1131T, V1220I, H1094R). PF-04217903 phosphate increases the incidence of subarachnoid hemorrhage and reduces survival rate without altering aneurysm formation, and also prevents lymph node metastasis induced by VEGF inhibition. PF-04217903 phosphate is applicable to research related to tumors (pancreas, stomach, lung, brain, colon, breast, kidney, melanoma, etc.), intracranial aneurysms and inflammatory diseases (gouty arthritis, neutrophilic pleuritis) [1] .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
